Ervogastat - Pfizer
Alternative Names: DGAT2i; PF-06865571Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Pfizer
- Class Amides; Ethers; Furans; Hepatoprotectants; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 08 Jan 2025 Chemical structure information added.
- 21 Feb 2024 Pfizer completes a phase II trial in Non-alcoholic steatohepatitis (Combination therapy) in Slovakia, Japan, Bulgaria, Canada, China, Hong Kong, India, Poland, Puerto Rico, South Korea, Taiwan (PO) (NCT04321031) (EudraCT2019-004775-39)
- 21 Feb 2024 Pfizer completes a phase II trial in Non-alcoholic steatohepatitis (Monotherapy) in Slovakia, Japan, Bulgaria, Canada, China, Hong Kong, India, Poland, Puerto Rico, South Korea, Taiwan (PO) (NCT04321031) (EudraCT2019-004775-39)